ClinVar Miner

Submissions for variant NM_001015877.2(PHF6):c.134G>A (p.Cys45Tyr)

dbSNP: rs132630299
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute RCV000011815 SCV005086003 pathogenic Borjeson-Forssman-Lehmann syndrome 2023-12-21 criteria provided, single submitter clinical testing Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with Borjeson-Forssman-Lehmann syndrome (BFLS; MIM#301900) in males; females heterozygous for pathogenic variants show an overlapping but distinct phenotype (PMID: 35662002). (I) 0109 - This gene is associated with X-linked recessive disease in males. Female with heterozygous variants may be affected; variant type and skewed X-inactivation may contribute to gender-specific phenotypes (PMID: 35662002). (I) 0200 - Variant is predicted to result in a missense amino acid change from cysteine to tyrosine. (I) 0253 - This variant is hemizygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. (SP) 0603 - Missense variant in a region that is highly intolerant to missense variation (high constraint region in DECIPHER). (SP) 0705 - No comparable missense variants have previous evidence for pathogenicity. (I) 0803 - This variant has limited previous evidence of pathogenicity in unrelated individuals. This variant has been observed as hemizygous and de novo in one individual with BFLS, and in several affected hemizygous males and unaffected carrier females from a large family with BFLS (PMIDs: 12415272, 15580208). (SP) 0903 - This variant has limited evidence for segregation with disease. This variant has observed as hemizygous in at least three affected males from one family with BFLS (PMID: 15580208). (SP) 1002 - This variant has moderate functional evidence supporting abnormal protein function. Functional studies in both patient cell lines and transfected cells show reduced PHF6 protein expression (PMIDs: 33772537, 30403997). (SP) 1205 - This variant has been shown to be maternally inherited (by trio analysis). (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign
GeneDx RCV004700218 SCV005201664 pathogenic not provided 2024-01-31 criteria provided, single submitter clinical testing Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 12415272)
OMIM RCV000011815 SCV000032048 pathogenic Borjeson-Forssman-Lehmann syndrome 2002-12-01 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.